ArticleVolume 45, Issue 8117707Open access Affiliations & Notes 1Department of Cell Biology, Emory University School of Medicine, Atlanta, GA, 30322, United States of America 2Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, 30322, United States of America 3Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, United States of America 4National Institute of Neurological Disorders and Stroke, Bethesda, MD, 20892,...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Riley E. Perszyk
Memantine treatment in individuals with GRIN gain‐of‐function variants is associated with improvements in behavior, development, and seizure frequency
We provide the first replication showing that memantine benefits only individuals with GRIN gain-of-function variants. Most prior GRIN case reports ignored variant function, leading to inappropriate memantine use and obscuring true clinical benefit. We could identify that an increased distance to the memantine binding site leads to clinical benefits in carriers of gain-of-function variants.
Functional Effects of Disease-Associated Variants Reveal That the S1-M1 Linker of the NMDA Receptor Critically Controls Channel Opening
Keywords Humans, Epilepsy, Intellectual Disability, Mutation, Missense, Receptors, N-Methyl-D-Aspartate, Glutamate receptors, Channelopathy, GRIN, GluN, Pre-M1, Translational study Abstract The short pre-M1 helix within the S1-M1 linker (also referred to as the pre-M1 linker) between the agonist-binding domain (ABD, S1) and the M1 transmembrane helix of the NMDA receptor (NMDAR) is devoid of missense variants within the healthy population but is a locus for de novo pathogenic variants...
Structural basis for channel gating and blockade in tri-heteromeric GluN1-2B-2D NMDA receptor
Keywords tri-heteromeric N-methyl-D-aspartate receptor channel gating channel blockade ketamine binding site subtype-selective negative allosteric modulation single-particle cryo-EM MD simulations electrophysiology Get full text access Log in, subscribe or purchase for full access. References 1. Hansen, K.B. ∙ Wollmuth, L.P. ∙ Bowie, D. ... Structure, function, and pharmacology of glutamate receptor ion channels Pharmacol. Rev. 2021; 73:298-487 2. Johnson, J.W. ∙ Ascher, P.
Selective Enhancement of the Interneuron Network and Gamma-Band Power via GluN2C/GluN2D NMDA Receptor Potentiation
Abstract N-methyl-D-aspartate receptors (NMDARs) comprise a family of ligand-gated ionotropic glutamate receptors that mediate a slow, calcium-permeable component to excitatory neurotransmission. The GluN2D subunit is enriched in GABAergic inhibitory interneurons in cortical tissue. Diminished levels of GABAergic inhibition contribute to multiple neuropsychiatric conditions, suggesting that enhancing inhibition may have therapeutic utility, thus making GluN2D modulation an attractive drug target.
Classification of Missense Variants in the N-Methyl-D-Aspartate Receptor GRIN Gene Family as Gain- Or Loss-of-Function.
Advances in sequencing technology have generated a large amount of genetic data from patients with neurological conditions. These data have provided diagnosis of many rare diseases, including a number of pathogenic de novo missense variants in GRIN genes encoding N-methyl-d-aspartate receptors (NMDARs). To understand the ramifications for neurons and brain circuits affected by rare patient variants, functional analysis of the variant receptor is necessary in model systems.
Differential responses of disease‐related GRIN variants located in pore‐forming M2 domain of N‐methyl‐D‐aspartate receptor to FDA‐approved inhibitors
CONFLICT OF INTEREST STATEMENT S.F.T. is a member of the SAB for Eumentis Therapeutics, Sage Therapeutics, and Combined Brain, is a member of the Medical Advisory Board for the GRIN2B Foundation and the CureGRIN Foundation, is an advisor to GRIN Therapeutics and Neurocrine, is co-founder of NeurOp Inc. and AgriThera Inc., and is a member of the Board of Directors of NeurOp Inc. H.Y. is PI on a research grant from Sage Therapeutics to Emory University School of Medicine.
De novo CLPTM1 variants with reduced GABAAR current response in patients with epilepsy
Supporting Information Filename Description epi17746-sup-0001-FigureS1.tifTIFF image, 13.7 MB Supplementary Material epi17746-sup-0002-FigureS2.tifTIFF image, 6.2 MB Supplementary Material
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Riley E.
Contact Riley E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack